Simply Better Brands Corp.’s No B.S. Skincare Brand Commences Its Partnership With UFC Champion Julianna Pena

2 years ago

No B.S. Skincare, in collaboration with Julianna Peña, Launches “Breaking stereotypes and b.s.” Campaign as Part of a Customer Acquisition…

Daré Bioscience to Participate in Maxim Group Women’s Health Panel

2 years ago

SAN DIEGO, July 07, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today…

Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference

2 years ago

President Tom Dubensky, Ph.D., to Share Expertise on Next Generation Immuno-Oncolgy TargetsSOUTH SAN FRANCISCO, Calif., July 07, 2022 (GLOBE NEWSWIRE) --…

Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in July

2 years ago

Mina Sooch CEO to Present at Ophthalmic Innovation Panel at the 11th Annual AECOS Summer Symposium and OIS Retina Innovation…

AGTC to Present at Upcoming American Society of Retina Specialists Annual Meeting

2 years ago

July 7, 2022 at 8:00 AM EDTGAINESVILLE, Fla., and CAMBRIDGE, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:…

Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome

2 years ago

Advances asset in the neuro-endocrine orphan disease spaceSCOUT-015 clinical trial currently has 9 activated US sites and patient screening commenced30+…

electroCore, Inc. Announces Study of gammaCore Sapphire™ for the Treatment of Post-COVID Syndrome

2 years ago

ROCKAWAY, N.J., July 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced Mayo Clinic is…

Humacyte Hosting Key Opinion Leader Webinar on Human Acellular Vessels™ in the Treatment of Vascular Trauma

2 years ago

Thursday, July 14, 2022 @ 11:30 a.m. ETDURHAM, N.C., July 07, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a…

Origin Therapeutics adds Clairvoyant Therapeutics to its Portfolio

2 years ago

Clairvoyant aims to develop and validate psychedelic therapy using psilocybin to treat addiction in Canada, the E.U., and the U.K.Vancouver,…